Literature DB >> 18665663

Acetylcholinesterase inhibitors may improve efficacy and reduce adverse effects of tricyclic antidepressants for depression.

Helmut Niederhofer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18665663     DOI： 10.2165/00002512-200825080-00008

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


× No keyword cloud information.
  7 in total

1.  Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

Authors:  I M Anderson
Journal:  J Affect Disord       Date:  2000-04       Impact factor: 4.839

2.  [Antidepressants: TCA versus SSRI versus other new agents].

Authors:  F Hay; P Linkowski
Journal:  Rev Med Brux       Date:  2004-09

Review 3.  A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders.

Authors:  Gary Figiel; Carl Sadowsky
Journal:  Curr Med Res Opin       Date:  2008-01       Impact factor: 2.580

Review 4.  Alternatives to atypical antipsychotics for the management of dementia-related agitation.

Authors:  Michael J Passmore; David M Gardner; Yvette Polak; Kiran Rabheru
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 5.  Adults with ADHD. An overview.

Authors:  P H Wender; L E Wolf; J Wasserstein
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

Review 6.  Factors associated with complex visual hallucinations during antidepressant treatment.

Authors:  Iacopo Cancelli; Gabriella Marcon; Matteo Balestrieri
Journal:  Hum Psychopharmacol       Date:  2004-12       Impact factor: 1.672

Review 7.  Rivastigmine in the treatment of Alzheimer's disease: an update.

Authors:  Maria Luisa Onor; Marianna Trevisiol; Eugenio Aguglia
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.